Skip to main content

Michael Aaron Morse

Professor of Medicine
Medicine, Medical Oncology
Duke Box 3233, Durham, NC 27710
Seeley G. Mudd Bldg, Rm 437, 10 Bryan Searle Dr., Durham, NC 27710

Selected Grants


Molecular Determinants of Health Disparities in Inflammatory Breast Cancer

ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2026

A Phase 1/2 open label study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab in subjects with advanced or metastatic solid tumors.

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2014 - 2024

A phase I/2 open label study of Nivolumab monotherapy or Nivolmab combined with Ipilmumab in subjects with advanced or metastatic solid tumors.

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2013 - 2022

Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy

ResearchCo Investigator · Awarded by Department of Defense · 2012 - 2022

Translational Research in Surgical Oncology

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2002 - 2022

Phase Ib/II Study of Pembrolizumab with Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)

Clinical TrialPrincipal Investigator · Awarded by Ipsen Biopharmaceuticals, Inc. · 2016 - 2022

A pilot study of active immunotherapy with CEA (6D) VRP vaccine (AVX701) in patients with stage III colon cancer.

Clinical TrialPrincipal Investigator · Awarded by AlphaVax, Inc. · 2013 - 2021

A Phase I dose escalation and cohort expansion study of ERY974

ResearchPrincipal Investigator · Awarded by Chugai Pharmaceutical Company, Ltd. · 2016 - 2020

Targeting the WNT/beta-catenin Pathway in Triple Negative Breast Cancer

ResearchPrincipal Investigator · Awarded by Department of Defense · 2013 - 2018

Long term follow up of subject who participated in aduro sponsored protocols

Clinical TrialPrincipal Investigator · Awarded by Aduro BioTech · 2015 - 2017

Novel Immune Modulating Cellular Vaccine for Prostate Cancer Immunotherapy

ResearchCo Investigator · Awarded by Department of Defense · 2013 - 2017

Clinical Oncology Research Career Development Program

ResearchMentor · Awarded by National Institutes of Health · 2009 - 2015

Targeting hCG-beta for Breast Cancer Immunotherapy

ResearchProject Leader · Awarded by National Institutes of Health · 2004 - 2009

Vaccination with Regulatory T Cell Depletion

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2006 - 2008

Biomarker Studies for Novel Anti-Cancer Agents

ResearchCo Investigator · Awarded by National Institutes of Health · 2003 - 2008

Immunotherapy using peptide MHC tetramer isolated Tcells

ResearchInvestigator · Awarded by National Institutes of Health · 2002 - 2007

Dendritic Cell Mobilization and Active Immunotherapy

ResearchInvestigator · Awarded by National Institutes of Health · 2001 - 2007

Planning a Duke Academic Public Private Partnership Program (AP4) Center

Institutional SupportCollaborator · Awarded by National Cancer Institute · 2004 - 2006

Cancer Care Quality Measures: Diagnosis and Treatment of Colorectal Cancer

ResearchInvestigator · Awarded by Agency for Healthcare Research and Quality · 2004 - 2005

Dexasome Based Immunotherapy of Lung Cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2004

Immunotherapy with TRICOM Modified Dendritic Cells

Clinical TrialInvestigator · Awarded by National Institutes of Health · 2001 - 2003

External Relationships


  • Alphasites
  • AstraZeneca
  • Cardinal Health, Inc.
  • Eisai Pharmaceuticals
  • Exelixis, Inc.
  • Alphasites
  • AstraZeneca
  • Cardinal Health, Inc.
  • Eisai Pharmaceuticals
  • Exelixis, Inc.
  • Genentech, Inc (Roche Holding)
  • Gerson Lehrman Group, Inc.
  • Guidepoint Global
  • Health Advances
  • ICON
  • IPSEN Innovation
  • MEDACorp (Leerink Swann & Co)
  • PPD, Inc.
  • Protagonist Therapeutics
  • Quintiles / IQvia
  • Regeneron Pharmaceuticals
  • Schlesinger Associates
  • Seagen
  • Servier
  • Society for immunotherapy of cancer
  • Taiho
  • Up To Date Inc/Wolters Kluwer Health
  • Yiviva

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.